Comparison of DNA and mRNA vaccines against cancer

Zohreh Jahanafrooz; Behzad Baradaran; Jafar Mosafer; Mahmoud Hashemzaei; Tayebeh Rezaei; Ahad Mokhtarzadeh; Michael R. Hamblin

doi:10.1016/j.drudis.2019.12.003

Comparison of DNA and mRNA vaccines against cancer

Zohreh Jahanafrooz
, Behzad Baradaran
, Jafar Mosafer
, Mahmoud Hashemzaei
, Tayebeh Rezaei
, Ahad Mokhtarzadeh
, Michael R. Hamblin

Laser Research Centre

Tabriz University of Medical Sciences
Torbat Heydarieh University of Medical Sciences
Zabol University of Medical Sciences
Arak University of Medical Sciences
Massachusetts General Hospital
Harvard University

Research output: Contribution to journal › Review article › peer-review

178 Citations (Scopus)

Abstract

Nucleic acid vaccines (NAVs) have recently been tested as a cancer therapy. DNA and mRNA vaccines deliver genetic information encoding tumor antigens (TAs) to the host, which then produces immune responses against cancer cells that express the TAs. Although NAVs are easy, safe, and simple to manufacture, they have not so far been considered viable alternatives to peptide vaccines. Choosing the right TAs, insufficient immunogenicity, and the immunosuppressive nature of cancer are some challenges to this approach. In this review, we discuss approaches that been used to improve the efficiency of anticancer NAVs.

Original language	English
Pages (from-to)	552-560
Number of pages	9
Journal	Drug Discovery Today
Volume	25
Issue number	3
DOIs	https://doi.org/10.1016/j.drudis.2019.12.003
Publication status	Published - Mar 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

ASJC Scopus subject areas

Pharmacology
Drug Discovery

Access to Document

10.1016/j.drudis.2019.12.003

Cite this

@article{02f88b5de5cb45ba8bd4e586f19af81a,

title = "Comparison of DNA and mRNA vaccines against cancer",

abstract = "Nucleic acid vaccines (NAVs) have recently been tested as a cancer therapy. DNA and mRNA vaccines deliver genetic information encoding tumor antigens (TAs) to the host, which then produces immune responses against cancer cells that express the TAs. Although NAVs are easy, safe, and simple to manufacture, they have not so far been considered viable alternatives to peptide vaccines. Choosing the right TAs, insufficient immunogenicity, and the immunosuppressive nature of cancer are some challenges to this approach. In this review, we discuss approaches that been used to improve the efficiency of anticancer NAVs.",

author = "Zohreh Jahanafrooz and Behzad Baradaran and Jafar Mosafer and Mahmoud Hashemzaei and Tayebeh Rezaei and Ahad Mokhtarzadeh and Hamblin, \{Michael R.\}",

note = "Publisher Copyright: {\textcopyright} 2019 Elsevier Ltd",

year = "2020",

month = mar,

doi = "10.1016/j.drudis.2019.12.003",

language = "English",

volume = "25",

pages = "552--560",

journal = "Drug Discovery Today",

issn = "1359-6446",

publisher = "Elsevier Ltd.",

number = "3",

}

TY - JOUR

T1 - Comparison of DNA and mRNA vaccines against cancer

AU - Jahanafrooz, Zohreh

AU - Baradaran, Behzad

AU - Mosafer, Jafar

AU - Hashemzaei, Mahmoud

AU - Rezaei, Tayebeh

AU - Mokhtarzadeh, Ahad

AU - Hamblin, Michael R.

PY - 2020/3

Y1 - 2020/3

N2 - Nucleic acid vaccines (NAVs) have recently been tested as a cancer therapy. DNA and mRNA vaccines deliver genetic information encoding tumor antigens (TAs) to the host, which then produces immune responses against cancer cells that express the TAs. Although NAVs are easy, safe, and simple to manufacture, they have not so far been considered viable alternatives to peptide vaccines. Choosing the right TAs, insufficient immunogenicity, and the immunosuppressive nature of cancer are some challenges to this approach. In this review, we discuss approaches that been used to improve the efficiency of anticancer NAVs.

AB - Nucleic acid vaccines (NAVs) have recently been tested as a cancer therapy. DNA and mRNA vaccines deliver genetic information encoding tumor antigens (TAs) to the host, which then produces immune responses against cancer cells that express the TAs. Although NAVs are easy, safe, and simple to manufacture, they have not so far been considered viable alternatives to peptide vaccines. Choosing the right TAs, insufficient immunogenicity, and the immunosuppressive nature of cancer are some challenges to this approach. In this review, we discuss approaches that been used to improve the efficiency of anticancer NAVs.

UR - https://www.scopus.com/pages/publications/85076847116

U2 - 10.1016/j.drudis.2019.12.003

DO - 10.1016/j.drudis.2019.12.003

M3 - Review article

C2 - 31843577

AN - SCOPUS:85076847116

SN - 1359-6446

VL - 25

SP - 552

EP - 560

JO - Drug Discovery Today

JF - Drug Discovery Today

IS - 3

ER -

Comparison of DNA and mRNA vaccines against cancer

Abstract

UN SDGs

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this